Kidney Week

Abstract: TH-PO818

Successful Eculizumab-Based Desensitization in ABO-Incompatible Living Donor Kidney Transplantation

Session Information

• Transplantation: Clinical - 2
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

• 2102 Transplantation: Clinical

Authors

• Heo, Ga Young, Yonsei University, Seoul, Korea (the Republic of)

Ga Young Heo, MD

• Jung, Minsun, Yonsei University, Seoul, Korea (the Republic of)

Minsun Jung, MD, PhD

• Piao, Honglin, Yonsei University, Seoul, Korea (the Republic of)

Honglin Piao, MD, MS

• Kim, Hyun-Jeong, Yonsei University, Seoul, Korea (the Republic of)

Hyun-Jeong Kim, MD

• Kim, Hyung Woo, Yonsei University, Seoul, Korea (the Republic of)

Hyung Woo Kim, MD

• Lee, Juhan, Yonsei University, Seoul, Korea (the Republic of)

Juhan Lee, MD

• Huh, Kyu ha, Yonsei University, Seoul, Korea (the Republic of)

Kyu ha Huh, MD, PhD

• Kim, Beom Seok, Yonsei University, Seoul, Korea (the Republic of)

Beom Seok Kim, MD, PhD

• Yang, Jaeseok, Yonsei University, Seoul, Korea (the Republic of)

Jaeseok Yang, MD, PhD

Background

High titers of anti-ABO antibodies in some patients are refractory to standard desensitization, leading to loss of KT opportunities or AMR.

Methods

Eculizumab-based desensitization was used to rescue high-titer ABOi KT patients refractory to plasmapheresis/rituximab-based desensitization.

Results

Initial titers of anti-ABO IgG antibodies in the two patients were 1:512 and >1:1024; the final pre-transplant titers after desensitization were 1:128 and 1:64. Both patients received eculizumab from the day of KT to two or four weeks post-KT and maintained stable renal function up to one-year without overt complications, despite early episodes of suspicious AMR or borderline TCMR. Molecular phenotype analysis of allograft biopsies using the B-HOT gene panel revealed that gene expression patterns in the ABOi KT with eculizumab group overlapped with those in the ABOi KT with AMR group more than in the ABOi KT without AMR group, except for complement pathway-related gene expression.

Conclusion

Short-term eculizumab-based desensitization therapy is promising for rescuing ABOi KT recipients with unacceptably high anti-ABO antibody titers refractory to plasmapheresis-based desensitization therapy.